Shared Genetic Loci Between Schizophrenia and White Blood Cell Counts Suggest Genetically Determined Systemic Immune Abnormalities
Permanent lenke
https://hdl.handle.net/10037/31992Dato
2023-06-15Type
Journal articleTidsskriftartikkel
Peer reviewed
Forfatter
Steen, Nils Eiel; Rahman, Zillur; Szabo, Attila; Hindley, Guy; Parker, Nadine; Cheng, Weiqiu; Lin, Aihua; O'Connell, Kevin S; Sheikh, Mashhood Ahmed; Shadrin, Alexey; Bahrami, Shahram; Karthikeyan, Sandeep; Hoseth, Eva Zsuzsanna; Dale, Anders M; Aukrust, Pål; Smeland, Olav Bjerkehagen; Ueland, Thor; Frei, Oleksandr; Djurovic, Srdjan; Andreassen, OleSammendrag
Study Design - GWAS results from SCZ (patients, n = 53 386; controls, n = 77 258) and WBC counts (n = 56 3085) were analyzed. We applied linkage disequilibrium score regression, the conditional false discovery rate method and the bivariate causal mixture model for analyses of genetic associations and overlap, and 2 sample Mendelian randomization to estimate causal effects.
Study Results - The polygenicity for SCZ was 7.5 times higher than for WBC count and constituted 32%–59% of WBC count genetic loci. While there was a significant but weak positive genetic correlation between SCZ and lymphocytes (rg = 0.05), the conditional false discovery rate method identified 383 shared genetic loci (53% concordant effect directions), with shared variants encompassing all investigated WBC subtypes: lymphocytes, n = 215 (56% concordant); neutrophils, n = 158 (49% concordant); monocytes, n = 146 (47% concordant); eosinophils, n = 135 (56% concordant); and basophils, n = 64 (53% concordant). A few causal effects were suggested, but consensus was lacking across different Mendelian randomization methods. Functional analyses indicated cellular functioning and regulation of translation as overlapping mechanisms.
Conclusions - Our results suggest that genetic factors involved in WBC counts are associated with the risk of SCZ, indicating a role of immune mechanisms in subgroups of SCZ with potential for stratification of patients for immune targeted treatment.